Pharmaceutical Interventions for Hearing Loss (PIHL) Working Group
There are currently no FDA-approved pharmaceutical preventative
measures or treatment options for hearing loss or tinnitus. However,
several promising agents are on the horizon as possible treatments. The
HCE has organized a working group known as the Pharmaceutical
Interventions for Hearing Loss, or PIHL group, which is dedicated to
advancing this field of medical research.
Bringing together experts from across the DoD, VA, academia, and
industry, the PIHL group coordinates subjects matter experts to develop
and disseminate:
- Current and comprehensive understanding of the state of the
science, including compilation of current research, ongoing clinical
trials and new study results,
- Evidence-based research methodology standards, and
- Capability-based requirements for technology transition to the DoD.
The PIHL group disseminates information through newsletters, available for download below.
For more information, or to join the PIHL group, please contact Ms. Tanisha Hammill at tanisha.hammill.ctr@us.af.mil.
All members are required to provide a recent CV and record of ethics
training in research, as well as a signed Conflict of Interest
Disclosure statement and Non-Disclosure Agreement.